Gary Starling is in the Protein Science Department at Merck Research Laboratories, based in the San Francisco Bay Area. His career has focused on the Discovery and Early Development of Biologic therapeutics. He began his career in the BioPharmaceutical industry at Bristol-Myers Squibb PRI working on extracellular domains of leukocyte antigens as targets for monoclonal antibodies. At CuraGen, Gary headed up the Inflammation group and had Project Management and Collaboration Management responsibilities for Biologics Programs. At PDL BioPharma Gary led the Autoimmune and Inflammatory Diseases group. PDL BioPharma spun out Facet Biotech, where Gary had responsibilities for Translational Research focused on Oncology Biologics Programs. Following the acquisition of Facet Biotech by Abbott Labs, Gary formed and led the Costimulation Early Biology Unit. The Protein Science Department at Merck drives the discovery of Biologics for all of Merck’s disease areas including Immuno-Oncology.
Gary received his BSc (Hons) from the University of Canterbury, Christchurch New Zealand and PhD from the University of Otago.